Safety and Dose Study of Targeted Lung Denervation in Moderate/Severe COPD Patients

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: Safety and Dose Study of Targeted Lung Denervation in Moderate/Severe COPD Patients ; volume:98 ; number:4 ; year:2019 ; pages:329-339
Respiration ; 98, Heft 4 (2019), 329-339

Creator: Valipour, Arschang
Shah, Pallav
Pison, Christophe
Ninane, Vincent
Janssens, Wim
Perez, Thierry
Kessler, Romain
Deslee, Gaetan
Garner, Justin
Abele, Christine
Hartman, Jorine E.
Slebos, Dirk-Jan

DOI: 10.1159/000500463

URN: urn:nbn:de:101:1-2019101000183944579105

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:37 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Valipour, Arschang
Shah, Pallav
Pison, Christophe
Ninane, Vincent
Janssens, Wim
Perez, Thierry
Kessler, Romain
Deslee, Gaetan
Garner, Justin
Abele, Christine
Hartman, Jorine E.
Slebos, Dirk-Jan

Other Objects (12)

Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes

Crossover Patient Outcomes for Targeted Lung Denervation in Moderate to Severe Chronic Obstructive Pulmonary Disease: AIRFLOW-2

Correction to: Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes

Bronchoscopic Targeted Lung Denervation in Patients with Severe Asthma: Preliminary Findings

Symptom profiles and inflammatory markers in moderate to severe COPD

Portable NIV for patients with moderate to severe COPD: two randomized crossover trials

Targeted ablation of p38α MAPK suppresses denervation-induced muscle atrophy

Targeted lung denervation in sheep: durability of denervation and long-term histologic effects on bronchial wall and peribronchial structures

Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD

MDI or nebulization in moderate to severe COVID-19 disease with COPD: which one is better?

Respiratory Sinus Arrhythmia Attenuation via Targeted Lung Denervation in Sheep and Humans

Clinical, physiologic, and radiographic factors contributing to development of hypoxemia in moderate to severe COPD: a cohort study

Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes

Crossover Patient Outcomes for Targeted Lung Denervation in Moderate to Severe Chronic Obstructive Pulmonary Disease: AIRFLOW-2

Correction to: Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes

Bronchoscopic Targeted Lung Denervation in Patients with Severe Asthma: Preliminary Findings

Symptom profiles and inflammatory markers in moderate to severe COPD

Portable NIV for patients with moderate to severe COPD: two randomized crossover trials

Targeted ablation of p38α MAPK suppresses denervation-induced muscle atrophy

Targeted lung denervation in sheep: durability of denervation and long-term histologic effects on bronchial wall and peribronchial structures

Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD

MDI or nebulization in moderate to severe COVID-19 disease with COPD: which one is better?

Respiratory Sinus Arrhythmia Attenuation via Targeted Lung Denervation in Sheep and Humans

Clinical, physiologic, and radiographic factors contributing to development of hypoxemia in moderate to severe COPD: a cohort study

Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes

Crossover Patient Outcomes for Targeted Lung Denervation in Moderate to Severe Chronic Obstructive Pulmonary Disease: AIRFLOW-2

Correction to: Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes

Bronchoscopic Targeted Lung Denervation in Patients with Severe Asthma: Preliminary Findings

Symptom profiles and inflammatory markers in moderate to severe COPD

Portable NIV for patients with moderate to severe COPD: two randomized crossover trials

Targeted ablation of p38α MAPK suppresses denervation-induced muscle atrophy

Targeted lung denervation in sheep: durability of denervation and long-term histologic effects on bronchial wall and peribronchial structures

Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD

MDI or nebulization in moderate to severe COVID-19 disease with COPD: which one is better?

Respiratory Sinus Arrhythmia Attenuation via Targeted Lung Denervation in Sheep and Humans

Clinical, physiologic, and radiographic factors contributing to development of hypoxemia in moderate to severe COPD: a cohort study

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Safety and Dose Study of Targeted Lung Denervation in Moderate/Severe COPD Patients

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes

Crossover Patient Outcomes for Targeted Lung Denervation in Moderate to Severe Chronic Obstructive Pulmonary Disease: AIRFLOW-2

Correction to: Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes

Bronchoscopic Targeted Lung Denervation in Patients with Severe Asthma: Preliminary Findings

Symptom profiles and inflammatory markers in moderate to severe COPD

Portable NIV for patients with moderate to severe COPD: two randomized crossover trials

Targeted ablation of p38α MAPK suppresses denervation-induced muscle atrophy

Targeted lung denervation in sheep: durability of denervation and long-term histologic effects on bronchial wall and peribronchial structures

Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD

MDI or nebulization in moderate to severe COVID-19 disease with COPD: which one is better?

Respiratory Sinus Arrhythmia Attenuation via Targeted Lung Denervation in Sheep and Humans

Clinical, physiologic, and radiographic factors contributing to development of hypoxemia in moderate to severe COPD: a cohort study

Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes

Crossover Patient Outcomes for Targeted Lung Denervation in Moderate to Severe Chronic Obstructive Pulmonary Disease: AIRFLOW-2

Correction to: Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes

Bronchoscopic Targeted Lung Denervation in Patients with Severe Asthma: Preliminary Findings

Symptom profiles and inflammatory markers in moderate to severe COPD

Portable NIV for patients with moderate to severe COPD: two randomized crossover trials

Targeted ablation of p38α MAPK suppresses denervation-induced muscle atrophy

Targeted lung denervation in sheep: durability of denervation and long-term histologic effects on bronchial wall and peribronchial structures

Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD

MDI or nebulization in moderate to severe COVID-19 disease with COPD: which one is better?

Respiratory Sinus Arrhythmia Attenuation via Targeted Lung Denervation in Sheep and Humans

Clinical, physiologic, and radiographic factors contributing to development of hypoxemia in moderate to severe COPD: a cohort study

Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes

Crossover Patient Outcomes for Targeted Lung Denervation in Moderate to Severe Chronic Obstructive Pulmonary Disease: AIRFLOW-2

Correction to: Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes

Bronchoscopic Targeted Lung Denervation in Patients with Severe Asthma: Preliminary Findings

Symptom profiles and inflammatory markers in moderate to severe COPD

Portable NIV for patients with moderate to severe COPD: two randomized crossover trials

Targeted ablation of p38α MAPK suppresses denervation-induced muscle atrophy

Targeted lung denervation in sheep: durability of denervation and long-term histologic effects on bronchial wall and peribronchial structures

Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD

MDI or nebulization in moderate to severe COVID-19 disease with COPD: which one is better?

Respiratory Sinus Arrhythmia Attenuation via Targeted Lung Denervation in Sheep and Humans

Clinical, physiologic, and radiographic factors contributing to development of hypoxemia in moderate to severe COPD: a cohort study

Related objects

Reset password